



Medgenics, Inc.
('Medgenics' or the 'Company')

MEDGENICS CEO TO PRESENT AT RODMAN AND RENSHAW ANNUAL GLOBAL INVESTMENT CONFERENCE

Misgav, Israel and London, UK – September 13, 2010 — Medgenics (AIM: MEDU/MEDG), the company that has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, today announced that Dr. Andrew Pearlman, Chief Executive Officer of Medgenics, will give a presentation at the Rodman & Renshaw Annual Global Investment Conference at The Palace Hotel in New York City on September 14, 2010 at 3:15 pm Eastern time.

The conference will include a series of one-on-one meetings with institutional investors. Investors interested in scheduling a meeting with Dr. Pearlman and the management team can facilitate a request by contacting the leslie.wolf-creutzfeldt@grayling.com or alternatively contact their Rodman & Renshaw representative directly.

NOTES TO EDITORS:

Notes to Editors:

Medgenics is a commercial-stage biopharmaceutical Company, developing its unique tissue-based Biopump platform technology to provide sustained-action protein therapy for the treatment of a range of chronic diseases. The first revenue generating commercial deal with a well known multinational pharmaceutical company was negotiated in late 2009.

Biopumps are made using 30 mm long tissue samples taken by needle biopsies from the lower layer of the patient's skin under local anaesthetic, and processed during 10-14 days to become "biofactories" producing the required protein. The requisite number of Biopumps are injected under the patient's skin to provide sustained protein production and delivery for many months. Dose can be reduced by ablating one or more Biopumps, or increased by injecting additional units. The Company is developing the Biopump to provide substantially greater safety and reliability in protein treatment in a more cost effective manner than offered by the existing injected protein therapies or current alternatives. Medgenics currently has three products in development based on this technology, addressing the indications of:

- Anaemia - using EPODURE, a Biopump producing erythropoietin (EPO)
- Hepatitis-C - using INFRADURE - a Biopump producing interferon-alpha (IFN-a)
- Haemophilia - using a Biopump to produce clotting Factor VIII

The Company's Phase I/II clinical trial using EPODURE to treat anaemia in patients with chronic kidney disease, has demonstrated proof of concept of the Biopump. Designed to produce and deliver a therapeutic dose of EPO steadily for six months or more, EPODURE Biopumps have already provided effective anaemia treatment in most of the longest participating patients for 6-20 months, even at the low administered dose. Medgenics intends to develop its innovative products and bring them to market via multiple strategic partnerships with major pharmaceutical and/or medical device companies. In addition to treatments for anaemia, hepatitis-C and haemophilia, Medgenics plans to develop and/or out-license a pipeline of future Biopump products targeting the large and rapidly growing global protein therapy market, which is forecast to reach US \$95 billion by the end of 2010. Other potential applications of Biopumps producing various proteins include multiple sclerosis, arthritis, paediatric growth hormone deficiency, obesity, and diabetes.

For further information, contact:

Medgenics, Inc.

Dr. Andrew L. Pearlman

Phone: +972 4 902 8900

Grayling, United States

Leslie Wolf-Creutzfeldt, Investor Relations

Phone: +1 646 284-9472

Email: leslie.wolf-creutzfeldt@grayling.com

CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, which include all statements other than statements of historical fact, including (without limitation) those regarding the Company's financial position, business strategy, plans and objectives of management for future operations. These statements relate to future events, prospects, developments and strategies. Forward-looking statements are sometimes identified by their use of the terms and phrases such as "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will," "will likely," "should," "could," "would," "may" or the negative of such terms and other comparable terminology. All such forward-looking statements are based on current expectations and are subject to risks and uncertainties. Should any of these risks or uncertainties materialize, or should any of the Company's assumptions prove incorrect, actual results may differ materially from those included within these forward-looking statements. Accordingly, no undue reliance should be placed on these forward-looking statements, which speak only as of the date made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, the events described in the forward-looking statements contained in this release may not occur.